treat it as the manufacturer statement it is and confirm against the documentation supplied with the lot
Independent third-party verification This batch has undergone additional third-party analytical verification through Janoshik Analytical Batch: TR10-260423 Internal HPLC purity: 99.13% Third-party verification: 99.62% independently confirmed high purity and identity consistency
CagriSema occupies a middle ground, with a higher side effect burden than cagrilintide alone but results that rival retatrutide
Funding The author(s) declared that financial support was received for this work and/or its publication
And, the more serious side effects, such as blood clots or congestive heart failure, are likely to occur in individuals who are already treating a preexisting condition, have heart conditions, or in those who are genetically predisposed to these conditions
Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al (2010) 5-fu metabolism in cancer and orally-administrable 5-FU drugs